... ENG

CLINICAL IMPACT Series

ESMO 2023 Breast Cancer : Clinical Impact on Your Practice

Review of ESMO 2023 data in Breast Cancer with Dr. Jamil Asselah, Dr. Rami J. Younan & Dr. Kim Ma

Dr. Tarantino - DESTINY BREAST

Q2: What are the steps you take to optimally manage ILD for patients on T-DXd (The 5 S Rules)?

Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on HER2-Low Breast Cancer and the DESTINY BREAST Trial

Dr. Tarantino - DESTINY BREAST

Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?

Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on HER2-Low Breast Cancer and the DESTINY BREAST Trial

ESMO 2023 - Neoadjuvant immunotherapy improves responses in HR-positive early breast cancer

Created by oncoXchange | November 2nd 2023

ASCO: Slight Revision In HER2 Testing Guidance for Breast Cancer

Created by oncoXchange | September 26th 2023

Exome sequencing identifies new breast cancer susceptibility genes

Created by oncoXchange | October 16th 2023

CLINICAL IMPACT Series

Insights & Innovations: Panel discussion on Patient-Reported Outcomes and AI in breast cancer

With Dr. Jamil Asselah, Dr. Tarek Hijal, Pr. Sylvie Lambert, Dr. Bertrand Lebouché & John Ioculano

ESMO 2023 - Antibody-drug conjugates improve outcomes in HER2-nonamplified breast cancer

Created by oncoXchange | November 2nd 2023